We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Gut Microbiome Classifier Improves Colorectal Cancer Risk Stratification

By LabMedica International staff writers
Posted on 02 Sep 2026

Colorectal cancer remains a leading cause of cancer mortality, and current noninvasive screening methods still miss many precancerous lesions. More...

Clinicians therefore need tools that improve risk stratification while fitting into stool-based testing workflows. Although the gut microbiome has been implicated in tumor biology, prior findings have often varied across cohorts and sequencing methods, limiting its clinical use. Building on this need, a large cross-cohort analysis has now defined a robust microbial signature and introduced a classifier that could inform future diagnostics and dietary interventions.

Researchers from the European Molecular Biology Laboratory (EMBL) and Leiden University Medical Center, working within the EU-funded CartoHostBug project, developed a machine-learning classifier trained on gut microbiome profiles. The model integrates data generated by different sequencing approaches and produces a quantitative “cancer-like microbiome” score for individual stool samples. The study was published in Cell Host & Microbe on July 8, 2026.

The analysis re-examined nearly 6,800 gut microbiome profiles drawn from 27 independent studies conducted in Germany, the Netherlands, and Switzerland. By harmonizing heterogeneous datasets, the team identified a generalizable microbial signature that distinguished colorectal cancer from non-cancer across populations, geographies, age groups, and both early- and late-onset disease. The approach addresses prior limitations of small, inconsistent cohorts that hindered translation.

To link noninvasive readouts with tumor biology, investigators analyzed 906 intestinal tissue samples. Microbes enriched in tumor tissue mirrored organisms driving the stool-based signature, and cancer-associated taxa appeared even in early-stage tumors. However, stool-based detection of precancerous adenomas remained challenging, reflecting weaker microbial signals that underscore the need for more sensitive strategies or multimodal combinations.

Diet emerged as a key modifier of the microbiome score. Lower dietary fiber intake correlated with more cancer-like patterns, while dietary intervention studies suggested that increasing fiber could reduce these scores. Species-level analysis refined understanding of Fusobacterium, showing that Fusobacterium nucleatum subsp. animalis was consistently more prevalent in cancer samples worldwide, whereas other subspecies displayed region-specific patterns. While the classifier is not a diagnostic test, it establishes a reference framework for future clinical tools and interventional research under CartoHostBug.

Related Links
EMBL
Leiden University Medical Center


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Hematology Consumables
Bioblood Devices
New
Gastrointestinal Panel
Xpert® GI Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: Shutterstock

Blood Test Could Guide Drug Selection to Prevent Repeat Heart Attacks and Strokes

Secondary prevention after myocardial infarction or stroke relies on antiplatelet therapy, yet responses vary widely and both recurrent thrombosis and bleeding remain persistent risks. In the United Kingdom,... Read more

Molecular Diagnostics

view channel
Image: Signatera uses ctDNA analysis to identify residual tumor-derived genetic material after definitive treatment (image credit: Adobe Stock)

Blood-Based MRD Test Predicts Recurrence Risk After Lung Cancer Surgery

Assessing recurrence risk after surgery for early-stage non-small cell lung cancer remains challenging, complicating adjuvant therapy and surveillance decisions. Blood-based molecular residual disease... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Pathology

view channel
Image: A new study demonstrates that vascular features in colorectal tumors could serve as prognostic biomarkers of disease outcome. (Image Credit: iStock)

Tumor Blood Vessel Features May Help Predict Colorectal Cancer Survival

Colorectal cancer outcomes vary widely, and tumor biology remains a key determinant of prognosis. Because neoplasms depend on a vascular supply, differences in intratumoral vessels may influence survival.... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: Central to the collaboration is the Enhanced Liver Fibrosis (ELF) test, a noninvasive blood test authorized in the U.S. to assess disease progression risk in patients with advanced fibrosis due to MASH and support patient management decisions. (Photo courtesy of Siemens Healthineers)

Siemens Healthineers and Novo Collaborate to Expand Access to Noninvasive Liver Testing

Metabolic dysfunction‑associated steatotic liver disease (MASLD) and its progressive form, metabolic dysfunction‑associated steatohepatitis (MASH), affect millions and are linked to obesity, type 2 diabetes,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.